Ross Garberich

Mr. Ross Garberich

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in The American Journal of Cardiology
Verified
Journal Article
Closed access
BMBarry J. Maron
Barry J. Maron
SCSusan A. Casey
Susan A. Casey
RCRaymond H. Chan
Raymond H. Chan
RGRoss Garberich
Ross Garberich
EREthan J. Rowin
Ethan J. Rowin
MMMartin S. Maron
Martin S. Maron

1 March 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
SGSantiago Garcia
Santiago Garcia
MFMiho Fukui
Miho Fukui
MDMarshall W. Dworak
Marshall W. Dworak
BOBrynn K. Okeson
Brynn K. Okeson
RGRoss Garberich
Ross Garberich
PSPaul Sorajja
Paul Sorajja
Background: Hypoattenuated leaflet thickening (HALT), identified on functional cardiac computed tomography (CTA), can affect valve function and clinical outcomes. The objective of this study was to assess the impact of HALT on clinical outcomes in patients treated with transcatheter aortic valve replacement (TAVR). Methods: In July 2015, Minneapolis Heart Institute implemented prospective screening of HALT at 30-day post-TAVR with CTA. Patients with evidence of HALT were recommended to initiate anticoagulation for 3 to 6 months with warfarin. Echocardiographic, ischemic, and bleeding outcomes were compared between HALT+ and HALT− patients. Survival rates were compared between HALT+ and HALT− patients using log-rank test, with Cox regression analysis used to identify variables independently associated with long-term death landmarked at time of CTA. This analysis included patients treated from July 1, 2015 to October 31, 2019. Results: Of 856 patients undergoing TAVR during the study period, 638 (75%) underwent CTA post-TAVR (median time 31 [30–37] days). HALT+ was evident in 79 (12.3%). HALT+ patients were more likely prescribed warfarin at 1, 3, and 12 months (all P <0.001) and had similar gradients compared with HALT− patients. After a median follow-up of 2.2 years (1.5-3.2), HALT+ patients had increased mortality (30% versus 20%; P =0.001). In Cox regression analysis, presence of HALT (hazard ratio, 1.83 [95% CI, 1.13–2.97]; P =0.014) remained independently associated with long-term mortality. Conclusions: In a large, real-world cohort of patients receiving TAVR followed by systematic screening with CTA 30-days post-procedure, HALT was found in 12% of patients and independently associated with long-term mortality. Findings of this nonrandomized, observational cohort study require independent validation.

1 April 2016 in The American Journal of Cardiology
Verified
Journal Article
Closed access
BMBarry J. Maron
Barry J. Maron
THTammy S. Haas
Tammy S. Haas
EDEmily R. Duncanson
Emily R. Duncanson
RGRoss Garberich
Ross Garberich
ABAndrew M. Baker
Andrew M. Baker
SMShannon Mackey-Bojack
Shannon Mackey-Bojack

1 February 2017 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
JMJesse M. Manunga
Jesse M. Manunga
ACAndrew Cragg
Andrew Cragg
RGRoss Garberich
Ross Garberich
JUJonathan A. Urbach
Jonathan A. Urbach
NSNeeda Skeik
Needa Skeik
TSTimothy M. Sullivan
Timothy M. Sullivan

12 April 2023 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
MGMario Gössl
Mario Gössl
LSLarissa Stanberry
Larissa Stanberry
GBGretchen Benson
Gretchen Benson
ESElizabeth Steele
Elizabeth Steele
RGRoss Garberich
Ross Garberich
MEMaurice Enriquez-Sarano
Maurice Enriquez-Sarano

1 March 2019 in American Heart Journal
Verified
Journal Article
Closed access
NHNick Huynh
Nick Huynh
STSarah Thordsen
Sarah Thordsen
TTTaylor Thomas
Taylor Thomas
SMShannon M. Mackey-Bojack
Shannon M. Mackey-Bojack
EDEmily R. Duncanson
Emily R. Duncanson
KHKevin M. Harris
Kevin M. Harris